Evidence map›Paper›PMID 42157383›Full record

ArticleCell cycle (Georgetown, Tex.)2026

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.

Zhou Zhou, Yuhang Chen, Ping Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhou ZhouOncology Department of Integrated Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, He Fei, Anhui, China.ORCID 0009-0008-1197-4085
Yuhang ChenDepartment of Integrative Oncology, Fudan University, Shanghai, China.
Ping LiOncology Department of Integrated Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, He Fei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

UBE2C, a key member of the ubiquitin-proteasome system, is overexpressed in various malignant tumors and correlates with poor prognosis. Our findings reveal that UBE2C expression is elevated in both pancreatic cancer cell lines and tissues compared to normal pancreatic cells and tissues, with this aberrant expression linked to a poor prognosis. Knockdown of UBE2C expression reduces pancreatic cancer cell proliferation, migration, and invasion, while significantly decreasing the phosphorylation of the PI3K/AKT/mTOR signaling pathway. Administration of the pathway activator SC79 reverses the inhibitory effects of UBE2C knockdown on the PI3K/AKT/mTOR pathway, restoring the proliferation, migration, and invasion of pancreatic cancer cells. These results suggest that UBE2C promotes pancreatic cancer progression

Indexed as

Disease ProgressionPancreatic NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesUbiquitin-Conjugating EnzymesCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessPhosphorylationMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesUBE2C protein, humanUbiquitin-Conjugating EnzymesAKTmTORpancreatic cancerPI3KUBE2C

Identifiers

PMID42157383
PMCPMC13196629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.